2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2522

Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response
Abstract Number: 1783

Phenome-Wide Association Study Identifies a New Association of Atrial Fibrillation in Males with Systemic Lupus Erythematosus
Abstract Number: 2140

Phenotypic and Functional Characteristics of Exosomes Isolated from Human Osteoarthritis (OA) Synovial Fluid
Abstract Number: 1951

Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Abstract Number: 1858

Phenotypical and Functional Characteristics of in Vitro Expanded Adipose-Derived Mesenchymal Stem Cells from Patients with Systemic Sclerosis
Abstract Number: 1855

Phosphodiesterase-5 Inhibitors Attenuate Fibrotic Phenotype and Restore Anti-Fibrotic Resopnses of Cutaneous Fibroblasts in Patients with Scleroderma
Abstract Number: 1758

Physical Activity and Sedentary Behaviour in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1055

Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences
Abstract Number: 1875

Physical Activity in Patients with Systemic Sclerosis
Abstract Number: 1539

Physician-Reported and Patient-Reported Anxiety and Depression in Rheumatoid Arthritis
Abstract Number: 2594

Physician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
Abstract Number: 2545

Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
Abstract Number: 1264

Pilot Evaluation Points to Male Specific Educational Programming for Males with SLE
Abstract Number: 880

Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Abstract Number: 1671

Pirfenidone Might Inhibit New Bone Formation in Spondyloarthritis: Proof of Concept Study Using Cell Culture Models

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].